Literature DB >> 153029

Treatment of advanced cancer of prostate with megestrol acetate.

J Geller, J Albert, S S Yen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 153029     DOI: 10.1016/0090-4295(78)90467-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  9 in total

Review 1.  Review of assessment of total androgen blockade as treatment of metastatic prostate cancer.

Authors:  J Geller
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

2.  Endocrine treatment of prostatic cancer.

Authors:  G Williams
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

3.  Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.

Authors:  C A Greig; N Johns; C Gray; A MacDonald; N A Stephens; R J E Skipworth; M Fallon; L Wall; G M Fox; K C H Fearon
Journal:  Support Care Cancer       Date:  2014-01-04       Impact factor: 3.603

4.  Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma.

Authors:  C D Schiller; M R Schneider; H Hartmann; A H Graf; H Klocker; G Bartsch
Journal:  Urol Res       Date:  1991

5.  Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

Authors:  B Warner; T J Worgul; J Drago; L Demers; M Dufau; D Max; R J Santen
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

Review 6.  Drug therapy of prostatic cancer.

Authors:  R P Huben; S D Perrapato
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

7.  Megestrol Acetate for Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer: An Old Answer for a New Problem.

Authors:  Maria La Vecchia; Daniele Galanti; Ivan Fazio; Rosario Paratore; Nicolò Borsellino
Journal:  Case Rep Oncol       Date:  2022-03-29

8.  Safety of megestrol acetate in palliating anorexia-cachexia syndrome in patients with castration-resistant prostate cancer.

Authors:  Sungwoo Hong; In Gab Jeong; Dalsan You; Jae-Lyun Lee; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Korean Med Sci       Date:  2013-05-02       Impact factor: 2.153

9.  Towards engineering hormone-binding globulins as drug delivery agents.

Authors:  Wee Lee Chan; Aiwu Zhou; Randy J Read
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.